Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a benzodiazepine derivative with anticonvulsant properties. It is thought to exert its effects by enhancing gamma-aminobutyric acid (GABA)ergic neurotransmission.
## Primary Indications
* Adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.
* Off-label uses include other seizure types and anxiety disorders, though evidence and dosing may vary.
## Adult Dosing
* **Lennox-Gastaut Syndrome (LGS):** Initiate at 5 mg twice daily. Increase dose by 5-10 mg every week to a target dose of 0.5-1 mg/kg/day, divided into two doses. The maximum recommended daily dose is 20 mg twice daily (40 mg/day). Dosing may be adjusted based on clinical response and tolerability.
## Pediatric Dosing
* **Lennox-Gastaut Syndrome (LGS) (2 to <10 years of age):** Initiate at 0.2-0.5 mg/kg/day, divided into two doses. Increase dose by 0.2-0.5 mg/kg/week to a target dose of 0.5-1 mg/kg/day, divided into two doses. Maximum daily dose is 5 mg twice daily (10 mg/day).
* **Lennox-Gastaut Syndrome (LGS) (10 to <30 kg):** Initiate at 5 mg once daily. Increase dose by 5 mg every week to a target dose of 0.5-1 mg/kg/day, divided into two doses. Maximum daily dose is 10 mg twice daily (20 mg/day).
* **Lennox-Gastaut Syndrome (LGS) (≥30 kg):** Initiate at 5 mg twice daily. Increase dose by 5 mg every week to a target dose of 0.5-1 mg/kg/day, divided into two doses. Maximum daily dose is 10 mg twice daily (20 mg/day).
*Note: Dosing for pediatric patients is complex and depends on age and weight. Precise titration based on clinical response and tolerability is crucial. Consult specific pediatric guidelines or local protocols.*
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. Consider initiating at a lower dose and titrating slowly.
* **Renal Impairment:** No specific dose adjustments are typically recommended, but caution is advised due to potential accumulation of active metabolites.
* **Concomitant CYP1A2 Inhibitors:** May require dose reduction.
* **Concomitant CYP2C19 Inducers:** May require dose increase.
## Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
* Severe respiratory impairment.
* Severe hepatic insufficiency.
* Myasthenia gravis.
* Sleep apnea.
## Adverse Effects
* **Common:** Somnolence, decreased appetite, aggression, behavioral problems, ataxia, irritability, fatigue, constipation, vomiting, upper respiratory tract infection, pneumonia, falls.
* **Serious:** Suicidal ideation/behavior, severe skin reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis), respiratory depression, dependence and withdrawal symptoms, paradoxical reactions.
## Key Drug Interactions
* **CNS Depressants (e.g., opioids, alcohol, other sedatives):** Increased risk of sedation, respiratory depression, and profound CNS depression.
* **CYP2C19 Inhibitors (e.g., fluconazole, fluvoxamine):** May increase clobazam levels.
* **CYP2C19 Inducers (e.g., rifampin):** May decrease clobazam levels.
* **CYP1A2 Inhibitors (e.g., fluvoxamine):** May increase clobazam N-desmethylclobazam metabolite levels.
* **Other Antiepileptic Drugs (AEDs):** Potential for additive CNS depression. Monitor for efficacy and toxicity. Clobazam may affect levels of other AEDs.
## Monitoring
* Monitor for signs of somnolence and fatigue, especially at the start of therapy or with dose increases.
* Assess for behavioral changes and suicidal ideation/behavior.
* Monitor for respiratory depression, especially when used with other CNS depressants.
* Monitor for signs of withdrawal if therapy is discontinued abruptly.
* Evaluate seizure frequency and severity.
## Clinical Pearls
* Clobazam has a long half-life, and steady-state concentrations are reached after approximately 2 weeks of daily dosing.
* Withdrawal symptoms can occur upon abrupt discontinuation. Taper the dose gradually.
* Clobazam can be used as an adjunctive treatment for specific seizure types, particularly those associated with LGS.
* Dose adjustments should be made slowly and with careful clinical monitoring.
* Be aware of the potential for drug interactions, especially with other CNS-acting medications and CYP enzyme modulators.
***
**Disclaimer:** This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and relevant guidelines for complete details and to ensure patient safety.
